Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22156293 | 0.86 | HTR7 (0.43) | AKR1C3AKR1C2CYP1A2CYP2A6MET | |
| SCHEMBL20946442 | 0.84 | MET (0.38) | CYP2A6METHTR2CHTR2AEPHX2 | |
| SCHEMBL15970997 | 0.84 | MET (0.38) | METHTR2CHTR2AEPHX2PPARG | |
| SCHEMBL4233570 | 0.79 | ALDH1A1 (0.50) | AKR1C3AKR1C2EPHX2PPARGALDH1A1 | |
| SCHEMBL20353819 | 0.77 | ALDH1A1 (0.41) | METHTR2CHTR2ABRD4CREBBP | |
| SCHEMBL22930082 | 0.76 | HTR2C (0.50) | AKR1C3AKR1C2CYP1A2CYP2A6HTR2C | |
| SCHEMBL8738295 | 0.76 | PRKCI (0.55) | CYP1A2CYP2A6HTR7 | |
| SCHEMBL599047 | 0.76 | HTR2A (0.53) | CYP1A2CYP2A6HTR2CHTR2ABRD4 | |
| SCHEMBL13872296 | 0.75 | HSD17B10 (0.31) | — | |
| SCHEMBL3035285 | 0.75 | AKR1C3 (0.39) | AKR1C3AKR1C2CYP1A2CYP2A6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | AKR1C3 2415/4885AKR1C2 2750/4885CYP1A2 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.